NIKKEI 225
37,628.48 -831.60 (-2.16%) HANG SENG
17,284.54 +83.27 (+0.48%) CRUDE OIL
83.75 +0.94 (+1.14%) GOLD FUTURES
2,344.20 +5.80 (+0.25%) DOW
38,085.80 -375.12 (-0.98%) Bitcoin GBP
51,824.18 +602.42 (+1.18%)
AtriCure, Inc. (ATRC)
After hours:
| Previous close | 23.05 |
| Open | 23.08 |
| Bid | 22.56 x 400 |
| Ask | 22.63 x 200 |
| Day's range | 22.07 - 22.88 |
| 52-week range | 22.07 - 59.61 |
| Volume | |
| Avg. volume | 727,680 |
| Market cap | 1.094B |
| Beta (5Y monthly) | 1.37 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.66 |
| Earnings date | 01 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 53.13 |
ZacksAtriCure's (ATRC) cryoSPHERE+ Probe to Aid in Pain Management
AtriCure (ATRC) unveils its cryoSPHERE+ cryoablation probe, which is intended to reduce freeze times and aid in postoperative pain management.
Business WireAtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management
MASON, Ohio, April 18, 2024--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has launched the cryoSPHERE®+ cryoablation probe, leveraging new insulation technology to reduce freeze times by 25% versus AtriCure’s legacy cryoSHPERE® device. The product is currently in an extended limited launch period in the United States, with
Business WireAtriCure to Announce First Quarter 2024 Financial Results
MASON, Ohio, April 10, 2024--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2024 financial results on Wednesday, May 1, 2024.
